George Zogopoulos, Ido Haimi, Shenin A Sanoba, Jessica N Everett, Yifan Wang, Bryson W Katona, James J Farrell, Aaron J Grossberg, Salvatore Paiella, Kelsey A Klute, Yan Bi, Michael B Wallace, Richard S Kwon, Elena M Stoffel, Raymond C Wadlow, Daniel A Sussman, Nipun B Merchant, Jennifer B Permuth, Talia Golan, Maria Raitses-Gurevich, Andrew M Lowy, Joy Liau, Joanne M Jeter, James M Lindberg, Daniel C Chung, Julie Earl, Teresa A Brentnall, Kasmintan A Schrader, Vivek Kaul, Chenchan Huang, Hersh Chandarana, Caroline Smerdon, John J Graff, Fay Kastrinos, Sonia S Kupfer, Aimee L Lucas, Rosalie C Sears, Randall E Brand, Giovanni Parmigiani, Diane M Simeone
BACKGROUND: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. METHODS: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study...
April 2024: Journal of the National Comprehensive Cancer Network: JNCCN